MétaCan
Menu
← Back to cohort

Persistence of AR signaling in small cell neuroendocrine prostate cancer (SCNC) and intermediate atypical carcinoma (IAC): Results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT).

2016· article· en· W2890301250 on OpenAlexaff
Rahul Aggarwal, Jack Youngren, Artem Sokolov, Jiaoti Huang, George Thomas, Lawrence D. True, Adam Foye, Joshi J. Alumkal, Charles J. Ryan, Tomasz M. Beer, Christopher P. Evans, Martin Gleave, Matthew B. Rettig, Joshua M. Stuart, Primo N. Lara, Theodore C. Goldstein, Li Zhang, Robert E. Reiter, Kim N., Eric J. Small

Bibliographic record

VenueJournal of Clinical Oncology · 2016
Typearticle
Languageen
FieldMedicine
TopicProstate Cancer Treatment and Research
Canadian institutionsBC Cancer AgencyUniversity of British Columbia
Fundersnot available
KeywordsMedicineAdenocarcinomaPathologyBiopsyProstate cancerCarcinomaCancerImmunohistochemistryBiologyInternal medicine

Abstract

fetched live from OpenAlex

5045 Background: De novo small cell neuroendocrine prostate carcinoma (SCNC) is an AR-null subtype observed in ~ 1% of patients (pts). We have observed a higher frequency of SCNC in castration-resistant metastatic biopsies (12%) as well as a morphologically distinct entity termed intermediate atypical carcinoma (IAC) (29%), both associated with shortened survival. We sought to determine whether treatment-emergent IAC and SCNC biopsies retained AR expression and signaling as compared with adenocarcinoma (adeno). Methods: Pts underwent a metastatic tumor biopsy of bone or soft tissue at one of 5 participating centers. Formalin fixed, paraffin-embedded tissue underwent pathologic review, fluorescence in situ hybridization (FISH) for assessment of AR amplification, and assessment of AR expression by immunohistochemistry (IHC). An AR transcriptional signature was applied to RNA sequencing (seq) data from frozen tissue. Results: Median serum PSA at the time of biopsy was 29 ng/mL (range 4-2250) for adeno, 123 (0.4-1600) for IAC, and 51 (0.6-930) for SCNC. AR amplification was seen in similar proportions of adeno (53%), IAC (58%), and SCNC tumors (53%) (p = ns). 2+/3+ nuclear AR expression by IHC was observed in 27/31 (87%), 21/24 (87%), and 7/9 (78%) of evaluable adenocarcinoma, IAC, and SCNC biopsies, respectively (p = ns). AR expression level by RNA-seq was likewise similar across histologies. AR transcriptional signature scores were similar between adeno and IAC histologies and lower in SCNC (p = 0.006), with considerable inter-patient variability noted in IAC. Conclusions: Contrary to the classical description of SCNC as an AR-null phenotype, the majority of metastatic SCNC and IAC biopsies were positive for AR amplification and expression. AR transcriptional activity was lower in SCNC, whereas IAC AR activity was comparable to adeno, potentially supporting IAC as a transitional state in which progressive loss of AR activity occurs. Longitudinal studies are ongoing to test this hypothesis. As novel therapeutic targets are identified in IAC and/or SCNC, continued co-targeting of the AR may be warranted. Clinical trial information: NCT02432001.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.006
Threshold uncertainty score0.011

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.106
GPT teacher head0.406
Teacher spread0.300 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations3
Published2016
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Clinical Oncology→Same topicProstate Cancer Treatment and Research→French-language works237,207→